Both total and phosphorylated tau are increased in Alzheimer's disease

Journal of Neurology Neurosurgery and Psychiatry

Volumn 70, Issue 5, 2001, Pages 624-630

  Sjogren M ^a   Davidsson, P ^a   Tullberg, M ^a   Minthon, L ^b   Wallin, A ^a   Wikkelso, C ^a   Granerus A K ^c   Vanderstichele, H ^d   Vanmechelen, E ^d   Blennow, K ^a,e  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c University of Health Sciences   (Sweden)

^d INNOGENETICS   (Belgium)

^e MEDICAL RESEARCH COUNCIL   (Sweden)

Author keywords

Cerebrospinal fluid; Hyperphosphorylated tau; Tau

Indexed keywords

PHOSPHOPROTEIN; PHOSPHOPROTEIN TAU; PROTEIN ANTIBODY; TAU PROTEIN; THREONINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BINSWANGER ENCEPHALOPATHY; CEREBROSPINAL FLUID LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DEMENTIA; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR WEIGHT; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; ISOELECTRIC FOCUSING; MIDDLE AGED; PHOSPHORYLATION; TAU PROTEINS;

EID: 0035033619     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.70.5.624     Document Type: Article

References (53)

1. Tomlinson BE, Corsellis JAN. Ageing and the dementias. In: Hume Adams J, Corsellis JAN, Duchen LW, eds. Greenfield's neuropathology. London: Edward Arnold; 1984:951-1025.
2. Spillantini MG, Goedert M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci 1998;21:428-33.
3. Vermersch P, Bordet R, Ledoze F, et al. Demonstration of a specific profile of pathological tau proteins in frontotemporal dementia cases. CR Acad Sci 1995;318:439-45.
4. Delacourte A, Buée L, Vermersch P. Immunochemistry in frontotemporal dementia. In: Pasquier F, Lebert F, Scheltens P, eds. Frontotemporal dementia. Dordrecht: ICG Publications, 1996:115-24.
5. Vandermeeren M, Mercken M, Vanmechelen E, et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993; 61:1828-34.
6. Arai H, Terajima M, Miura M, et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol 1995;38:649-52.
7. Blennow K, Wallin A, Agren H, et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995;26:231-45.
8. Jensen M, Basun H, Lannfelt L. Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neurosci Lett 1995;186:189-91.
9. Mori H, Hosoda K, Matsubara E, et al. Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci Lett 1995;186:181-3.
10. Motter R, Vigo Pelfrey C, Kholodenko D, et al. Reduction of β-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995;38: 643-8.
11. Vigo-Pelfrey C, Seubert P, Barbour R, et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology 1995;45:788-93.
12. Arai H, Morikawa Y, Higuchi M, et al. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun 1997; 236:262-4.
13. Green AJ, Harvey RJ, Thompson EJ, et al. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci Lett 1999;259: 133-5.
14. Mecocci P, Cherubini A, Bregnocchi M, et al. Tau protein in cerebrospinal fluid: a new diagnostic and prognostic marker in Alzheimer disease? Alzheimer Dis Assoc Disord 1998;12:211-14.
15. Sjögren M, Minthon L, Davidsson P, et al. CSF levels of tau, β-amyloid 42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm 2000;105:563-79.
16. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393:702-5.
17. Tullberg M, Månsson JE, Fredman P, et al. CSF sulfatide distinguishes between normal pressure hydrocephalus and subcortical arteriosclerotic encephalopathy. J Neurol Neurosurg Psychiatry 2000;69:74-81.
18. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd ed, revised. Washington, DC: Cambridge University Press; 1987.
19. Risberg J, Gustafson L. 133Xe cerebral blood flow in dementia and in neuropsychiatry research. In: Magistretti PL, ed. Functional radionuclide imaging of the brain. New York: Raven Press; 1983:151-9.
20. Brun A, Englund B, Gustafsson L, et al. clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994;57:416-18.
21. Sjögren M, Edman Å, Wallin A. Symptomatological characteristics distinguish between frontotemporal dementia and vascular dementia with a dominating frontal lobe syndrome. Int J Geriatr Psychiatry 1997;12:656-61.
22. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report on the NINCDS-ADRDA Work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984;34:939-44.
23. Bennett DA, Wilson RS, Gilley DW, et al. Clinical diagnosis of Binswanger's disease. J Neurol Neurosurg Psychiatry 1990;53:961-5.
24. Wallin ACJ, Granérus A-K. Prevalence of dementia and regional brain syndromes in long-standing Parkinson's disease. Parkinsonism and Related Disorders 1999;5:103-10.
25. Folstein M, Folstein S, McHugh P. Mini-mental state, a practical method for grading the cognitive state of patients for the clinician. J Psychol Res 1975;12:189-98.
26. Blennow K, Fredman P, Wallin A, et al. Protein analysis in cerebrospinal fluid: I. Influence of concentration gradients for proteins on cerebrospinal fluid/serum albumin ratio. Eur Neurology 1993;33:126-8.
27. Tibbling G, Link H, Ohman S. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest 1977;37:385-90.
28. Vanmechelen E, Vanderstichele H, Davidsson P, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49-52.
29. Kane JW, Gowland E. A method for the identification of apolipoprotein E isoforms employing chemical precipitation and flat bed isoelectric focusing in agarose. Ann Clin Biochem 1986;23:509-13.
30. Skoog I, Vanmechelen E, Andreasson LA, et al. A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85 year olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele. Neurodegeneration 1995;4:433-42.
31. Mercken M, Vandermeeren M, Lubke U, et al. Monoclonal antibodies with selective specificity for Alzheimer tau are directed against phosphatase-sensitive epitopes. Acta Neuropathol Berl 1992;84:265-72.
32. Mercken M, Vandermeeren M, Lubke U, et al. Affinity purification of human tau proteins and the construction of a sensitive sandwich enzyme linked immunosorbent assay for human tau detection. J Neurochem 1992;58:548-53.
33. Goedert M, Jakes R, Crowther RA, et al. Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. Biochem J 1994;301:871-7.
34. Goedert M, Jakes R, Crowther RA, et al. The abnormal phosphorylation of tau at Ser-202 in Alzheimer's disease recapitulates phosphorylation during development. Proc Natl Acad Sci 1993;90:5066-70.
35. Goedert M, Jakes R, Vanmechelen E. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett 1995;189:167-9.
36. Davidsson P, Westman A, Puchades M, et al. Characterization of proteins from human cerebrospinal fluid by a combination of preparative two dimensional liquid phase electrophoresis and matrix assisted laser desorption/ ionization time of flight mass spectrometry. Anal Chem 1999;71:642-7.
37. Davidsson P, Puchades M, Blennow K. Identification of synaptic vesicle, pre and postsynaptic proteins in human cerebrospinal fluid using liquid phase isoelectric focusing. Electrophoresis 1999;20:431-7.
38. Leary JJ, Brigati DJ, Ward DC. Rapid and sensitive colorimetric method for visualizing biotin labeled DNA probes hybridized to DNA or RNA immobilized in nitrocellulose bio-plots. Proc Natl Acad Sci (USA) 1983;80:4045-9.
39. Andreasen N, Vanmechelen E, Van de Voorde A, et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry 1998;64:298-305.
40. Galasko D, Chang L, Motter R, et al. High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998;55:937-45.
41. Ishiguro K, Ohno H, Arai H, et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett 1999;270:91-4.
42. Wolozin B, Davies P. Alzheimer's related neuronal protein A68: specificity and distibution. Ann Neurol 1987;22:521-6.
43. Johnson GV, Seubert P, Cox TM, et al. The tau protein in human cerebrospinal fluid in Alzheimer's disease consists of proteolytically derived fragments. J Neurochem 1997;68: 430-3.
44. Zemlan FP, Rosenberg WS, Luebbe PA, et al. Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins. J Neurochem 1999;72:741-50.
45. Molina JA, Benito-Leon J, Jimenez-Jimenez FJ, et al. Tau protein concentrations in cerebrospinal fluid of non-demented Parkinson's disease patients. Neurosci Lett 1997; 238:139-11.
46. Bissette G, Smith WH, Dole KC, et al. Alterations in Alzheimer's disease-associated protein in Alzheimer's disease frontal and temporal cortex. Arch Gen Psychiatry 1991;48:1009-12.
47. Harrington CR, Mukeatova-Ladinska EB, Hills R, et al. Measurement of distinct immunochemical presentations of tau protein in Alzheimer disease. Proc Natl Acad Sci 1991; 88:5842-6.
48. Mukaetova-Ladinska EB, Harrington CR, Hills R, et al. Regional distribution of paired helical filaments and normal tau proteins in aging and in Alzheimer's disease with and without temporal lobe involvement. Dementia 1992;3:61-9.
49. Bramblett GT, Trojanowski JQ, Lee VMY. Regions with abundant neurofibrillary pathology in human brain exhibit a selective reduction in levels of binding component tau and accumulation of abnormal tau-isoforms (A68 proteins). Lab Invest 1992;66:212-22.
50. Khatoon S, Grundke-Iqbal I, Iqbal K. Brain levels of microtubule-associated protein tau are elevated in Alzheimer's disease: a radioimmunoslot-blot assay for nanograms of the protein. J Neurochem 1992;59:750-3.
51. Harrington CR, Perry RH, Perry EK, et al. Senile dementia of Lewy body type and Alzheimer type are biochemically distinct in terms of paired helical filaments and hyperphosphorylated tau protein. Dementia 1994;5:215-8.
52. Goedert M, Wischik CM, Crowther RA, et al. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci 1988;85:4051-5.
53. Oyama F, Shimada H, Oyama R, et al. Differential expression of β-amyloid protein precursor (APP) and tau mRNA in the aged human brain: individual variability and correlation between APP-751 and four-repeat tau. J Neuropathol Exp Neurol 1991;50:560.